Abstract Library

#3010 International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Pancreatic Neuroendocrine Tumors

Introduction: A prediction model to predict recurrence within 5 years after surgery for nonfunctional pancreatic neuroendocrine tumors (PanNets) was recently published. This model includes WHO tumor grade, lymph node status and perineural invasion as predictors.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Heidsma C, Van Dieren S, Gill A, Engelsman A, Strobel O,

Keywords: Prediction model, recurrence, pancreatic neuroendocrine,

#1372 The Role of Interval CT Scanning in Patients Undergoing Palliative Chemotherapy for Metastatic Neuroendocrine Tumours (NETs)

Introduction: In NET, radiological response to chemotherapy is often delayed and the importance of interval-imaging during treatment has not been determined.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Miller R, Childs A, Gillmore R, Mayer A, Thirlwell C,

Keywords: NETs, chemotherapy, imaging,

#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results

Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: PESCE V

Authors: Grance G, Pesce V, Bestanti C, O'Connor J, Roca E,

Keywords: NET, quality of life, symptom burden, supportive care,

#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy

Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Childs A, Kirkwood A, Lee A, Caplin M, Gillmore R,

Keywords: chemotherapy, Ki-67,

#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary

Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Quaglia A, Vivian G, Mulholland N, Sherwood R,

Keywords: unknown primary, survival ,